AI Regulatory Writing Software Validation: A Practical Guide

This guide is for medical writing leads, regulatory operations teams, and QA or system owners preparing an AI-assisted writing workflow for use. Here, qualification means assembling evidence that the configured workflow is suitable for its stated purpose. Your organization's applicable quality procedures determine the formal terminology, documentation, and approval route.

Assyro publishes this guide. Its evidence plan and fictional examples are editorial recommendations, not an account of a vendor trial or an approved validation protocol. Regulatory sources were checked on September 14, 2026.

Decide what the evidence must establish

Start with the decision you need to make. “The software is validated” leaves the reader unable to tell what was evaluated, who reviewed it, or which use is permitted.

Keep these records connected without substituting one for another. A well-supported paragraph can be placed in a technically defective package. A technically conformant package can contain an unsupported clinical conclusion. The eCTD validation guide addresses the package workflow; the task here is establishing evidence for the writing process that precedes it.

The practical route is to define the use, identify consequential failures, agree evidence and acceptance criteria, evaluate the configured workflow, and issue a bounded decision. Each stage supplies the next: without an agreed source boundary, for example, a reviewer cannot distinguish legitimate source retrieval from reliance on an obsolete document.

Establish applicability before choosing a protocol

Three primary sources help frame this decision, but they have different scopes and authority.

FDA's January 2025 draft, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, remained draft guidance when checked. Section II excludes operational uses, including submission drafting, that do not affect patient safety, drug quality, or the reliability of nonclinical or clinical study results. It encourages early FDA engagement when scope is uncertain. Do not treat its proposed credibility framework as a binding qualification protocol for every writing application. Conversely, calling a workflow “drafting” does not resolve whether its actual function falls within that exclusion. FDA draft, section II, page 3.

The January 2026 FDA/EMA Guiding Principles of Good AI Practice in Drug Development concern AI used to generate or analyze evidence across the drug lifecycle. They emphasize context, risk, traceable data, assessment of human-AI interactions, and lifecycle management. These are guiding principles, not certification of a writing product. FDA/EMA principles, pages 1–2.

For electronic records, establish which records and signatures fall under applicable requirements. FDA's August 2003 Part 11 scope guidance distinguishes submitted electronic records from intermediate material that is not otherwise required to be maintained under a predicate rule. Its validation section describes enforcement discretion for specified Part 11 provisions while retaining applicable predicate-rule obligations; it recommends a justified, documented risk assessment. It does not impose an additional universal validation requirement. FDA Part 11 guidance, sections III.B.2 and III.C.1.

Ask your quality and regulatory owners to document the applicable regime, required records, use of electronic signatures, and rationale for the chosen assurance approach. This guide does not determine EU, UK, Canadian, device, clinical-trial, or manufacturing obligations from a US writing scenario. “Used in pharma” is too broad to settle those questions.

Define the use narrowly enough to evaluate

A useful intended-use statement describes the transformation and the remaining human work. Consider this fictional starting point:

Permitted use: Produce an English draft of a specified safety-results paragraph from sponsor-approved aggregate tables and an approved terminology sheet. Identify the supporting source version and location for each factual statement. A trained medical writer checks every statement against those sources before the document enters the established approval process.

Excluded uses: Deriving new results from participant-level data, determining causality, adjudicating events, generating unsupported clinical conclusions, translating documents, or releasing text without review.

These boundaries constrain both the evaluation and daily use. If users regularly paste unapproved spreadsheet extracts into the application, evidence obtained solely from approved PDF tables no longer represents their workflow.

Capture the document section, source types, language, user roles, permitted calculations, citation expectations, output format, and final record location. Identify how source approval is established and what happens when two supplied versions disagree. An instruction to “use the latest source” is insufficient if the application cannot distinguish an approved revision from a newer working copy.

For the configured system, record the application release, model identifier or vendor release reference, prompt and template versions, retrieval settings, and document-processing components available to you. Where the supplier does not expose an internal detail, record that limitation and the alternative evidence offered. A missing version record should remain an unresolved issue when it prevents you from identifying what was evaluated.

The handoff from this stage is a use statement and configuration record that the writing lead, system owner, and quality reviewer can all interpret the same way.

Turn writing risks into observable acceptance criteria

Evaluate the failures that would change a reviewer's conclusion. Grammar quality and fluent prose are secondary if the paragraph changes an analysis population, drops a qualification, or attributes a claim to a source that does not support it.

The following is a proposed evidence plan for the fictional workflow. It is not an authority-prescribed minimum.

Define “critical” in advance for the particular section. In this example, an incorrect safety denominator or invented causal assessment is critical. A permitted spelling variant is not. Do not let a high average quality score compensate for a failure that violates an essential use condition.

Choose cases across the source formats and document structures you actually intend to support. Include correct inputs, missing information, contradictory revisions, difficult tables, and plausible but incorrect reviewer drafts. Reserve cases that were not used to tune prompts, so the evaluation does not merely repeat examples the configuration was designed around.

Plan repeated generations where variable output could matter. Record all agreed attempts, including poor outputs and retries. An attractive fifth attempt does not erase four prior failures. There is no universal sample count in this guide: justify the selection and repetition against your workflow, failure consequences, and uncertainty. A small exercise demonstrates particular behavior; it does not estimate a reliable population-wide error rate.

Work through a source-to-output qualification example

The following records and candidate sentences are invented for this article. They contain no patient data and were manually composed to expose specific reasoning errors. No vendor application generated them, and no technical validator was run.

Establish the source boundary

Assume the source owner provides this manifest and approves version 2 for the current paragraph:

For this exercise, the writing instructions permit calculating a percentage when the population and calculation are identified. They require the safety-population result in the main sentence. A separate, explicitly labeled randomized-population comparison is permitted. That permission matters: a workflow that prohibits new calculations would reach a different decision on the comparison sentence.

The checkable arithmetic is 6 ÷ 48 × 100 = 12.5% for the safety population and 6 ÷ 60 × 100 = 10% for the randomized population. The older result, 5 ÷ 48 × 100 ≈ 10.4167%, rounds to 10.4%, but belongs to the superseded source.

Adjudicate the candidate sentences

These decisions apply to individual statements, not an entire software release. A finished paragraph would also need to meet the instruction to include the main safety result. The acceptable randomized-population sentence cannot replace that required sentence.

Now introduce a meaningful boundary case: remove the approval status from both S-07 revisions. The responsible action is to seek a source-owner decision. Selecting version 2 solely because its number is larger does not meet the source-governance requirement. The content task remains blocked until authority is resolved, even if the selected numbers happen to be correct.

Reject the wrong evidence of success

Suppose someone offers a clean eCTD report to resolve the failed safety sentence. Ask which rule evaluates whether six participants out of the safety population of 48 equals 12.5%. Unless there is separately demonstrated content checking for that proposition, the technical report does not answer the question.

FDA currently lists validation criteria 4.6 for eCTD 3.2.2 and 1.6 for eCTD 4.0, with support beginning August 28, 2026 for those versions. These are separate US technical criteria sets; neither version number is a qualification standard for AI writing. Identify the correct package criteria independently of the writing evidence. FDA 3.2.2 standards, FDA 4.0 standards.

Make a bounded release decision

For a real evaluation, retain the source manifest, approved answer key, configured workflow, original outputs, reviewer findings, corrected outputs, and deviation decisions. Preserve the first output when a writer edits it; otherwise you cannot distinguish software behavior from the reviewer's successful repair.

Assign owners to the evidence. The source owner settles approved content and versions. The writing lead defines acceptable narrative and reviewer competence. The system owner establishes configuration and supplier dependencies. QA or the designated quality authority evaluates the evidence and deviations under the applicable procedure. The person authorizing use needs the unresolved issues, not only a polished demonstration.

Use a decision that describes its consequences:

• Permit the defined use: Required evidence is complete, essential criteria are met, and the documented review and operating controls are available. State the permitted documents, source formats, configuration, and users.
• Restrict the use: A narrower workflow has supporting evidence and enforceable boundaries. For example, permit approved machine-readable tables while excluding scanned sources that were not adequately evaluated.
• Do not release the proposed use: A critical requirement failed, an essential control is ineffective, or consequential evidence remains unknown. Name the corrective work and evidence needed to reconsider.

For the example, correcting 10% to 12.5% makes that sentence accurate. It does not establish that source selection and denominator handling are reliable. Investigate whether the error arose in source extraction, retrieval, instruction handling, generation, or review. Re-evaluate the affected path with fresh cases; do not merely store the corrected paragraph as proof that the system passed.

An unresolved causal assessment can be an acceptable output boundary when the intended use requires escalation. An inability to identify the evaluated configuration is a different unknown: it can prevent a defensible release decision. Record the difference instead of assigning both a reassuring “passed with comments.”

Keep the evidence valid through change

Qualification covers an operating arrangement. When that arrangement changes, decide what earlier evidence remains relevant before relying on it.

Agree how suppliers communicate consequential updates and what evidence your team can retain. If advance version pinning is unavailable, assess whether release notices, configuration records, post-change checks, and use restrictions provide adequate control. Do not claim reproducibility that the supplied service cannot support.

Monitor the failure types that matter after release: wrong-source citations, unsupported statements, denominator corrections, unresolved prompts, and reviewer escapes. Establish owners and escalation conditions. A serious new error should trigger investigation and an impact assessment of affected work, even when routine aggregate scores look stable.

Bring the use statement to the software discussion

Start the next conversation with one approved source pack, the intended-use statement, and the acceptance rules demonstrated here. Ask the supplier to show the actual configured workflow and identify what evidence it provides versus what your organization must create. A generic “validated platform” claim is a starting question, not the release decision.

If your writing work is connected to FDA eCTD 4.0 preparation, Assyro is our first recommendation to evaluate, subject to demonstrating your exact writing, source, review, and output requirements. This is our publisher preference. Assyro's technical eCTD scope does not establish that it has passed this writing exercise; eCTD 3.2.2 is not currently supported. A required 3.2.2 workflow needs another supported technical route.

Bring those requirements to an Assyro workflow discussion. Keep qualification ownership and the evidence decision explicit whichever product you choose.